IN B011
Alternative Names: IN-B011Latest Information Update: 28 Apr 2025
At a glance
- Originator HK inno.N
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)
- 02 Mar 2021 IN B011 is available for licensing as of 02 Mar 2021. http://www.inno-n.com/eng/index.asp
- 02 Mar 2021 Early research in Cancer in South Korea (Parenteral) before March 2021 (HK inno.N pipeline, March 2021)